Section 05 · What federal rules mean for your pharmacy
Wolverine Legal Status is unclear for pharmacy-made drugs
The FDA lists BPC-157 and the TB-500 fragment as withdrawn nominations, outside Category 2. That listing grants no general permission for pharmacies to make either substance.
Wolverine Legal Status does not give pharmacies clear permission
You may want a yes-or-no answer about pharmacy use. Neither substance has FDA approval, and no use of the blend is approved.
The FDA records both nominations as withdrawn. BPC-157 and the TB-500 fragment no longer sit in Category 2; their safety warnings remain on the FDA page [9].
Category 2 meant the FDA saw a chance of serious harm. Leaving that group did not mean either substance was safe, approved, rejected, or lawful for your pharmacy to make; it only meant the requests were no longer in that group.
Category 1 was a different group that got a brief pause from FDA action during review. The risk group did not get that pause for one-patient drugs [9][10].
An FDA advisory agenda put pharmacy use of these ingredients up for discussion. The agenda concerned BPC-157 and TB-500 as potential starting substances, without settling their eligibility [11].
Putting a meeting on the calendar does not settle the rule. It does not promise that your pharmacy can get or make the blend.
These distinctions come from public FDA pages, and the rules may change. This page offers no medical or legal advice and sells nothing.
FDA Category 2 meant possible harm, not approval
Federal law lets a state-licensed pharmacy make some drugs after a prescriber writes an order for a named patient [10]. That route covers one person at a time.
A second route lets an FDA-registered site prepare larger batches. That site supplies offices or stock; it isn't where you have a usual pharmacy visit [10].
Both routes limit which starting substances may be used. An individual prescription or an office order does not by itself establish that a starting substance meets those rules.
While the substances were in Category 2, the FDA did not promise to hold off on action against pharmacies using them. The nominations are now withdrawn; that status carries no general authorization to compound [10].
The earlier Category 2 entries covered BPC-157 and the TB-500 fragment of Thymosin Beta-4 [9]. The FDA warned about an immune reaction, dirt in a vial, and contents that might not match the label.
The FDA entry uses TB-500 to mean the short piece from Thymosin Beta-4. It doesn't mean the full protein [9].
A prescription decision and pharmacy eligibility are separate
For any drug made to order, a licensed prescriber must first see the patient. You may meet the prescriber face to face or through a lawful video or phone service [10].
If the drug fits the care and the law, the prescriber may write an order for that person. A state-licensed pharmacy may fill that person's order when the drug is eligible [10].
A registered site can make larger batches for an office or other stock. These two routes explain who may make an eligible drug; they don't make these substances eligible.
A remote visit only changes how you meet the prescriber. The same compounding requirements still apply [10].
The BPC-157 and TB-500 requests were pulled, and both left Category 2. That unresolved bulk-substance question is distinct from an individual prescribing decision [9][10].
A prescription alone doesn't settle whether a pharmacy may use these substances. At mypromise.com, Promise Peptides lists prescription-only Wolverine (BPC-157 and TB-500) and prescribes it if its licensed U.S. clinician agrees.
The FDA record leaves approval and pharmacy use unresolved
FDA approval is missing for BPC-157 and TB-500, and sport bars both.
Neither substance is approved for human use, and the FDA has approved no use for the blend. Both requests left Category 2, but that did not approve pharmacy use [9][10].
The World Anti-Doping Agency also bars both substances. That matters if you compete or take sports drug tests.
A prescribing route does not settle the blend's compounding status.
The FDA hasn't approved BPC-157, TB-500, or the blend for people. The withdrawn nominations do not supply general permission for patient-specific compounding [9][10][11].
Both remain barred in sport. A seller's label may differ from the material inside.
Federal records don't clearly permit a pharmacy to make BPC-157.
The FDA shows that the BPC-157 request was pulled and left Category 2. The same entry keeps the safety warning and gives no clear permission for a one-patient pharmacy [9][10].
The cited FDA advisory agenda concerned discussion of substances for patient-specific compounding. The agenda named BPC-157, but it was not a final list [11].
The latest posted record still leaves Wolverine pharmacy use unclear.
The blend isn't an approved drug. The FDA previously placed BPC-157 and the TB-500 fragment in Category 2.
Both requests were later pulled, so both left Category 2. The advisory materials are part of the review record; they are not a final authorization to compound [9][11].
Neither nomination withdrawal nor an advisory discussion gives a pharmacy general permission to use these ingredients. A one-patient pharmacy still can't point to this review as approval.
Side effects from the blend remain unknown in people.
No controlled human safety test has used both substances [6][7]. Thymosin Beta-4 can help cells travel and new vessels grow, which raises concern about cancer spread [4].
Long-term BPC-157 safety in people is also unknown [8]. Reviews still treat both substances as unproved.
TB-500 raises a cancer concern but hasn't been proved to cause cancer.
Several cancers contain high amounts of Thymosin Beta-4. Moving cells and new blood vessels may also feed the spread of a tumor [4].
That TB-500 warning comes from Thymosin Beta-4 lab and tumor work, not a blend test in people. It doesn't prove that TB-500 causes cancer or that BPC-157 shares the same risk.